Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency

Susana Gonzalez, Thozhukat Sathyapalan, Zeeshan Javed, Stephen Atkin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.

Original languageEnglish
Article number56
JournalFrontiers in Endocrinology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - 23 Feb 2018

Fingerprint

Growth Hormone
Succinate Dehydrogenase
Exercise
Muscles
Placebos
Somatomedins
Fats
Quadriceps Muscle
Group Psychotherapy
Adipose Tissue
Lipids
Biopsy
Therapeutics
Serum

Keywords

  • Cardiovascular risk factors
  • Exercise performance
  • GH deficiency
  • Mitochondrial dysfunction
  • Succinate dehydrogenase

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency. / Gonzalez, Susana; Sathyapalan, Thozhukat; Javed, Zeeshan; Atkin, Stephen.

In: Frontiers in Endocrinology, Vol. 9, No. FEB, 56, 23.02.2018.

Research output: Contribution to journalArticle

@article{b0d5360e846b4bfd813d7c9bcd5563fc,
title = "Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency",
abstract = "Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2{\%} (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.",
keywords = "Cardiovascular risk factors, Exercise performance, GH deficiency, Mitochondrial dysfunction, Succinate dehydrogenase",
author = "Susana Gonzalez and Thozhukat Sathyapalan and Zeeshan Javed and Stephen Atkin",
year = "2018",
month = "2",
day = "23",
doi = "10.3389/fendo.2018.00056",
language = "English",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency

AU - Gonzalez, Susana

AU - Sathyapalan, Thozhukat

AU - Javed, Zeeshan

AU - Atkin, Stephen

PY - 2018/2/23

Y1 - 2018/2/23

N2 - Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.

AB - Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.

KW - Cardiovascular risk factors

KW - Exercise performance

KW - GH deficiency

KW - Mitochondrial dysfunction

KW - Succinate dehydrogenase

UR - http://www.scopus.com/inward/record.url?scp=85042497846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042497846&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00056

DO - 10.3389/fendo.2018.00056

M3 - Article

AN - SCOPUS:85042497846

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - FEB

M1 - 56

ER -